<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709692</url>
  </required_header>
  <id_info>
    <org_study_id>53333</org_study_id>
    <nct_id>NCT04709692</nct_id>
  </id_info>
  <brief_title>Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria</brief_title>
  <official_title>An Open Label Phase 2a Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of (+)-SJ000557733 (SJ733) With or Without Cobicistat in Adult Patients With Acute, Uncomplicated Malaria Over a 42 Day Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R. Kiplin Guy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Health Innovative Technology Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociacion Civil Selva Amazonica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2a trial recruits adult patients with uncomplicated P. vivax or P. falciparum&#xD;
      blood-stage malaria mono-infection. The study drug SJ733 will be administered to examine its&#xD;
      antimalarial efficacy, safety, and tolerability. This study also evaluates whether or not a&#xD;
      fixed dose of the pharmacoenhancer cobicistat when given in combination with SJ733&#xD;
      significantly improves drug efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an adaptive open label Phase 2a study to examine the antimalarial efficacy, safety,&#xD;
      and tolerability of SJ733 in adult patients with uncomplicated P. vivax or P. falciparum&#xD;
      blood-stage malaria monoinfection. SJ733 will be administered orally once every day for three&#xD;
      consecutive days, with or without a fixed dose of the pharmacoenhancer cobicistat. The Phase&#xD;
      1 clinical data (completed under a US IND) and PK/PD models suggest that SJ733 is most likely&#xD;
      to be curative as a 3-daily-dose pharmacoenhanced therapy, due to its moderately rapid&#xD;
      clearance. There will be 1-3 cohorts with each cohort containing two treatment arms, P.&#xD;
      falciparum (a) and P. vivax (b). Cohort progression will be managed independently for each&#xD;
      treatment arm. Interim analysis will determine whether the data for a given treatment arm&#xD;
      meets the success criteria, is inconclusive, or meets the failure criteria. Antimalarial&#xD;
      efficacy will be examined over the period of 42 days. Additional aims are to characterize the&#xD;
      safety and pharmacokinetics of SJ733. The results of this trial will identify active,&#xD;
      well-tolerated doses for investigation in a larger Phase 2b clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">December 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 4, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>There are 6 treatment arms (three cohorts, each with P. falciparum and P.vivax arms).Cohort progression will be managed independently for each treatment arm. Interim analysis will determine whether the data for each arm meets the success criteria</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Crude Adequate Clinical and Parasitological Response (ACPR)</measure>
    <time_frame>14 days for each arm</time_frame>
    <description>Crude Adequate Clinical and Parasitological Response (ACPR) defined as the absence of microscopically determined parasitemia (thick smear)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Incidence and seriousness of treatment emergent adverse events as defined in Adult Toxicity Tables</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant abnormal laboratory values</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Incidence and seriousness of clinically significant abnormal laboratory values including changes from baseline in (biochemistry and hematology)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant abnormal vital signs</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Incidence and seriousness of clinically significant abnormal vital signs including changes from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with signs and symptoms of uncomplicated malaria</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>symptoms (fever clearance time) or physical examination signs related to uncomplicated P. vivax or P. falciparum malaria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite clearance time</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Parasite clearance kinetics as measured by microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite reduction rate</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Parasite clearance kinetics as measured by microscopy - PRR (parasite reduction rate) and parasitemia half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asexual parasite clearance time</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Parasite clearance kinetics of asexual parasites as measured by microscopy including half life of clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in asexual parasites from baseline</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Percentage reduction of asexual parasites as determined by microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>11 days for each arm</time_frame>
    <description>AUC of SJ733 and its metabolite SJ506 will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma drug concentration (Cmax)</measure>
    <time_frame>11 days for each arm</time_frame>
    <description>Cmax of SJ733 and its metabolite SJ506 will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>11 days for each arm</time_frame>
    <description>Tmax of SJ733 and its metabolite SJ506 will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Clearance</measure>
    <time_frame>11 days for each arm</time_frame>
    <description>Drug clearance of SJ733 and its metabolite SJ506 will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crude Adequate Clinical and Parasitological Response (ACPR)</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Crude ACPR at Days 28, 35, and 42 as measured by microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of malaria infection</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Recurrence of either P. vivax or P. falciparum malaria as measured by signs and symptoms or malaria and microscopy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Crude Adequate Clinical and Parasitological Response (ACPR), PCR adjusted</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Crude Adequate Clinical and Parasitological Response (ACPR) as adjusted by quantitative PCR of parasite DNA at Days 7, 14, 28, 35, and 42</description>
  </other_outcome>
  <other_outcome>
    <measure>Recurrence of malaria infection, PCR adjusted</measure>
    <time_frame>42 days for each arm</time_frame>
    <description>Recurrence of either P. vivax or P. falciparum malaria as measured by PCR</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Malaria, Falciparum</condition>
  <condition>Malaria, Vivax</condition>
  <arm_group>
    <arm_group_label>Arm 1 A (cohort 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1 B (cohort 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 A (cohort 2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>600 mg SJ733 administered orally once every day for three consecutive days for patients with P.vivax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 B (cohort 2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>600 mg SJ733 administered orally once every day for three consecutive days for patients with P.falciparum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 A (cohort 3)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 B (cohort 3)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(+)-SJ000557733 (SJ733)</intervention_name>
    <description>Anti-Malarial</description>
    <arm_group_label>Arm 1 A (cohort 1)</arm_group_label>
    <arm_group_label>Arm 1 B (cohort 1)</arm_group_label>
    <arm_group_label>Arm 2 A (cohort 2)</arm_group_label>
    <arm_group_label>Arm 2 B (cohort 2)</arm_group_label>
    <arm_group_label>Arm 3 A (cohort 3)</arm_group_label>
    <arm_group_label>Arm 3 B (cohort 3)</arm_group_label>
    <other_name>SJ733</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged 18 to 70 years of age (inclusive) at screening.&#xD;
&#xD;
          2. Body weight between 45 kg and 90 kg inclusive&#xD;
&#xD;
          3. Presence of mono-infection of P. falciparum or P. vivax confirmed by:&#xD;
&#xD;
               1. Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic&#xD;
                  temperature ≥ 38°C, or history of fever in the previous 24 hours (history of&#xD;
                  fever must be documented) and,&#xD;
&#xD;
               2. Microscopically confirmed parasite infection: 1,000 to 40,000 asexual parasite&#xD;
                  count/µL blood&#xD;
&#xD;
          4. Written informed consent provided by participant, in accordance with local practice.&#xD;
             If the participant is unable to write, witnessed consent is permitted according to&#xD;
             local ethical considerations.&#xD;
&#xD;
          5. Ability to swallow oral medication.&#xD;
&#xD;
          6. Ability and willingness to participate and to comply with the study requirements&#xD;
&#xD;
          7. Agreement to hospitalization for at least 102 hours and/or until malarial parasites&#xD;
             are not detected by microscopy on 2 consecutive occasions.&#xD;
&#xD;
          8. Agreement to come back to the hospital on Days 7, 10 or 11, 14, 17 or 18, 21, 24 or&#xD;
             25, 28, 35, and 42.&#xD;
&#xD;
          9. Women of child-bearing potential, has a negative pregnancy test at screening, and&#xD;
             agrees to comply with one of the following during the treatment stage of the study and&#xD;
             for a period of 90 days after stopping study drug:&#xD;
&#xD;
               1. Use of oral, implantable, or injectable hormonal contraceptive, either combined&#xD;
                  or progestogen alone used in conjunction with barrier method as defined below.&#xD;
&#xD;
               2. Use of an intrauterine device with a documented failure rate of &lt;1% per year.&#xD;
&#xD;
               3. Barrier method consisting of either condom or diaphragm.&#xD;
&#xD;
               4. Male partner who is sterile prior to the female subject's entry into the study&#xD;
                  and is the sole sexual partner for that female.&#xD;
&#xD;
               5. Complete abstinence from intercourse for 2 weeks prior to administration of study&#xD;
                  drug, throughout the study and for a period of 90 days after stopping study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Signs and symptoms of severe/complicated malaria according to the World Health&#xD;
             Organization Criteria 2010 (Attachment 1: Definition of Severe Malaria)&#xD;
&#xD;
          2. Mixed Plasmodium infection.&#xD;
&#xD;
          3. Severe vomiting, defined as more than three times in the 24 hours prior to inclusion&#xD;
             in the study, or severe diarrhea defined as 3 or more watery stools per day.&#xD;
&#xD;
          4. Severe malnutrition (defined as the weight-for-height being below -3 standard&#xD;
             deviation or less than 70% of median of the NCHS/WHO normalized reference values)&#xD;
&#xD;
          5. Presence of a significant medical or psychiatric condition, or any other serious or&#xD;
             chronic clinical condition requiring hospitalization, or any other condition that in&#xD;
             the opinion of the investigator precludes participation in the study.&#xD;
&#xD;
          6. Female patients must not be either lactating or pregnant as demonstrated by a negative&#xD;
             serum point-of-care pregnancy test pre-dose (the result of the pre-dose assessment&#xD;
             must be confirmed negative prior to dosing).&#xD;
&#xD;
          7. Employment under the direct supervision of the investigators or study staff.&#xD;
&#xD;
          8. Clinically significant alterations to hematologic or clinical chemistry parameters&#xD;
             that in the opinion of the investigator precludes participation in the study,&#xD;
             including:&#xD;
&#xD;
               1. AST/ALT &gt; 3 x upper limit of normal range (ULN) and total bilirubin is normal&#xD;
&#xD;
               2. AST/ALT &gt; 2 x ULN and total bilirubin is &gt;1 and &lt;1.5 x ULN and conjugated&#xD;
                  bilirubin is &gt; 35% of the total bilirubin&#xD;
&#xD;
               3. Total bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
               4. Serum creatinine levels &gt; 2 x ULN&#xD;
&#xD;
               5. Hb level &lt; 8 g/dL&#xD;
&#xD;
               6. Platelet level &lt; 50,000/mm3&#xD;
&#xD;
          9. Participation in a clinical study of another investigational small molecule within 30&#xD;
             days or investigational biologic within 90 days prior to study enrollment or planning&#xD;
             to begin such participation during the study.&#xD;
&#xD;
         10. Have received any antimalarial treatment (alone or in combination) in the past&#xD;
             containing:&#xD;
&#xD;
               1. Piperaquine, mefloquine, naphthoquine or sulphadoxine / pyrimethamine within the&#xD;
                  previous 6 weeks&#xD;
&#xD;
               2. Amodiaquine or chloroquine within the previous 4 weeks&#xD;
&#xD;
               3. Any artemisinin (artesunate, artemether, arteether or dihydroartemisinin)&#xD;
                  quinine, halofantrine, lumefantrine and any other anti-malarial treatment or&#xD;
                  antibiotics with antimalarial activity (including cotrimoxazole, tetracyclines,&#xD;
                  quinolones and fluoroquinolones, and azithromycin) within the past 14 days&#xD;
&#xD;
         11. Any medication from the list of prohibited medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro L Cuentas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación Civil Selva Amazónica (ACSA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jared Hammill, PhD.</last_name>
    <phone>859-257-0484</phone>
    <email>Jared.Hammill@uky.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodney K Guy, PhD</last_name>
    <phone>859-257-5290</phone>
    <email>Kip.Guy@uky.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asociación Civil Selva Amazónica (ACSA)</name>
      <address>
        <city>Iquitos</city>
        <state>Loreto</state>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro L Cuentas, MD, PhD</last_name>
      <phone>511-994-273-050</phone>
      <email>alejandro.llanos.c@upch.pe</email>
    </contact>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <reference>
    <citation>Jiménez-Díaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gómez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martínez MS, Miller G, Rodríguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62. doi: 10.1073/pnas.1414221111. Epub 2014 Dec 1. Erratum in: Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5764.</citation>
    <PMID>25453091</PMID>
  </reference>
  <reference>
    <citation>Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, Smith AM, Stewart TB, Branum KC, Freeman BB 3rd, Patel ND, John E, Chalon S, Ost S, Heine RN, Richardson JL, Christensen R, Flynn PM, Van Gessel Y, Mitasev B, Möhrle JJ, Gusovsky F, Bebrevska L, Guy RK. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infect Dis. 2020 Aug;20(8):964-975. doi: 10.1016/S1473-3099(19)30611-5. Epub 2020 Apr 8.</citation>
    <PMID>32275867</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>R. Kiplin Guy</investigator_full_name>
    <investigator_title>Professor and Dean</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

